Sei Investments Co. lessened its stake in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 28.1% during the fourth quarter, HoldingsChannel reports. The firm owned 68,272 shares of the biopharmaceutical company’s stock after selling 26,719 shares during the period. Sei Investments Co.’s holdings in Alexion Pharmaceuticals were worth $7,917,000 as of its most recent SEC filing.
Other hedge funds also recently added to or reduced their stakes in the company. Jennison Associates LLC boosted its position in shares of Alexion Pharmaceuticals by 720.0% during the 3rd quarter. Jennison Associates LLC now owns 5,332,636 shares of the biopharmaceutical company’s stock worth $748,116,000 after purchasing an additional 4,682,336 shares in the last quarter. Factory Mutual Insurance Co. boosted its position in shares of Alexion Pharmaceuticals by 104.5% during the 4th quarter. Factory Mutual Insurance Co. now owns 358,500 shares of the biopharmaceutical company’s stock worth $42,873,000 after purchasing an additional 183,200 shares in the last quarter. Creative Planning boosted its position in shares of Alexion Pharmaceuticals by 72.2% during the 4th quarter. Creative Planning now owns 27,773 shares of the biopharmaceutical company’s stock worth $3,321,000 after purchasing an additional 11,642 shares in the last quarter. USA Financial Portformulas Corp bought a new position in shares of Alexion Pharmaceuticals during the 3rd quarter worth about $3,632,000. Finally, IFC Holdings Incorporated FL bought a new position in shares of Alexion Pharmaceuticals during the 3rd quarter worth about $861,000. 95.38% of the stock is currently owned by institutional investors.
A number of research firms recently weighed in on ALXN. Zacks Investment Research lowered shares of Alexion Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, February 14th. SunTrust Banks set a $172.00 target price on shares of Alexion Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, February 12th. BMO Capital Markets upped their target price on shares of Alexion Pharmaceuticals from $177.00 to $180.00 and gave the stock an “outperform” rating in a report on Friday, February 9th. Stifel Nicolaus restated a “buy” rating and issued a $151.00 target price on shares of Alexion Pharmaceuticals in a report on Friday, February 9th. Finally, Morgan Stanley upped their target price on shares of Alexion Pharmaceuticals from $148.00 to $151.00 and gave the stock an “overweight” rating in a report on Friday, February 9th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and twenty-one have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $152.77.
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) opened at $121.33 on Tuesday. Alexion Pharmaceuticals, Inc. has a 52-week low of $96.18 and a 52-week high of $149.34. The firm has a market cap of $26,364.57, a P/E ratio of 23.46, a PEG ratio of 1.10 and a beta of 1.16. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.62 and a current ratio of 3.10.
Alexion Pharmaceuticals (NASDAQ:ALXN) last released its earnings results on Thursday, February 8th. The biopharmaceutical company reported $1.48 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.09 by $0.39. Alexion Pharmaceuticals had a net margin of 12.48% and a return on equity of 12.94%. The firm had revenue of $909.70 million during the quarter, compared to the consensus estimate of $880.38 million. During the same period in the prior year, the firm earned $1.26 EPS. The company’s revenue was up 9.5% compared to the same quarter last year. sell-side analysts anticipate that Alexion Pharmaceuticals, Inc. will post 6.12 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Alexion Pharmaceuticals, Inc. (ALXN) Shares Sold by Sei Investments Co.” was first reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this article on another site, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The correct version of this article can be viewed at https://www.tickerreport.com/banking-finance/3225413/alexion-pharmaceuticals-inc-alxn-shares-sold-by-sei-investments-co.html.
Alexion Pharmaceuticals Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.